Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short term Debt (2019)

Summit Therapeutics' Short term Debt history spans 1 years, with the latest figure at $105000.0 for Q4 2019.

  • For Q4 2019, Short term Debt changed N/A year-over-year to $105000.0; the TTM value through Dec 2019 reached $105000.0, changed N/A, while the annual FY2019 figure was $105000.0, N/A changed from the prior year.
  • Short term Debt reached $105000.0 in Q4 2019 per SMMT's latest filing.
  • In the past five years, Short term Debt ranged from a high of $105000.0 in Q4 2019 to a low of $105000.0 in Q4 2019.